Figure 5.

Effect of ICI 118551 (ICI) treatment on the expression of amyloid beta (Aβ) accumulation related protein in amyloid precursor protein/presenilin 1 double transgenic (AD-TG) mice.

(A) The protein levels of presenilin 1 (PS1), amyloid precursor protein (APP), phosphorylation of APP (p-APP), secreted amyloid precursor protein-α (sAPPα), secreted amyloid precursor protein-β (sAPPβ) and amyloid beta (6E10) in the hippocampus were measured by western blot assay. (B) Protein signal intensity was quantified by ImageJ software and normalized by β-actin expression. *P < 0.05, **P < 0.01, vs. non-TG/NaCl. Data are expressed as the mean ± SD (n = 8, one-way analysis of variance followed by the least significant difference test). Wild type control (non-TG) and AD-TG mice were sub-grouped: saline control group, injections of 0.9% NaCl, termed non-TG/NaCl and AD-TG/NaCl; β2-AR antagonist treatment group, mice were administered ICI 118551 (1 mg/kg per day, intraperitoneally), termed non-TG/ICI and AD-TG/ICI. Experiments were conducted in triplicate.